The Global (3-Chloropyrazin-2-yl)MethanaMine Hydrochloride Market was valued at USD 18.7 Million in 2024 and is projected to reach USD 28.4 Million by 2029, growing at a Compound Annual Growth Rate (CAGR) of 8.7% during the forecast period (2024–2029). This growth is being driven by increasing incidence of hematological cancers, rising demand for targeted cancer therapies, and the essential role of this chemical intermediate in Acalabrutinib production for treating B-cell malignancies.

As the pharmaceutical industry advances toward precision medicine and targeted oncology treatments, the spotlight is on the key chemical manufacturers who are driving production efficiency, quality control, and scalable synthesis pathways. In this blog, we profile the Top 10 Companies in the (3-Chloropyrazin-2-yl)MethanaMine Hydrochloride Industry—a mix of specialized chemical producers, pharmaceutical intermediates suppliers, and API manufacturers shaping the future of oncology drug development.

---

🔟 1. Unichemist

Headquarters: Shanghai, China
Key Offering: High-purity (≥98%) (3-Chloropyrazin-2-yl)MethanaMine Hydrochloride

Unichemist is among the leading manufacturers of pharmaceutical intermediates, offering high-purity (3-Chloropyrazin-2-yl)MethanaMine Hydrochloride for API synthesis. Their chemical division serves pharmaceutical companies, research institutions, and contract manufacturing organizations with growing investments in scalable synthesis technologies and process optimization.

Production Capabilities:

• Advanced chemical synthesis processes

• Partnerships with global pharmaceutical manufacturers

• Committed to achieving GMP compliance across manufacturing facilities

Download FREE Sample Report:
(3-Chloropyrazin-2-yl)MethanaMine Hydrochloride Market – View in Detailed Research Report

---

9️⃣ 2. Anmaibo Biomedical

Headquarters: Henan, China
Key Offering: Pharmaceutical Intermediates, High-Purity Chemical Compounds

Anmaibo Biomedical operates in multiple countries and supplies critical intermediates to pharmaceutical companies developing oncology treatments. The company is a significant player in active pharmaceutical ingredient supply chains, aiming to meet both regulatory and quality standards in cancer drug manufacturing.

Production Capabilities:

• Strategic investments in chemical synthesis technology

• Collaboration with research institutions to optimize synthetic routes

---

8️⃣ 3. INNOPHARMCHEM

Headquarters: Shanghai, China
Key Offering: (3-Chloropyrazin-2-yl)MethanaMine Hydrochloride with various purity grades

INNOPHARMCHEM’s chemical division is expanding its pharmaceutical intermediates portfolio through process optimization and scale-up capabilities. The company is also engaged in custom synthesis services to support oncology drug development.

Production Capabilities:

• Custom synthesis capabilities for pharmaceutical clients

• Quality control systems ensuring ≥98% purity standards

---

7️⃣ 4. Hubei Norna Technology

Headquarters: Hubei, China
Key Offering: Pharmaceutical Intermediates, Specialty Chemicals

Hubei Norna Technology is one of China’s leading chemical suppliers, serving both domestic pharmaceutical manufacturers and international markets. The company is heavily invested in process chemistry optimization, particularly through advanced purification techniques and analytical method development.

Production Capabilities:

• Goal of expanding production capacity by 40% by 2026

• China’s largest pharmaceutical intermediate production facility in Wuhan

Download FREE Sample Report:
(3-Chloropyrazin-2-yl)MethanaMine Hydrochloride Market – View in Detailed Research Report

---

6️⃣ 5. Shanghai Canbi Pharma

Headquarters: Shanghai, China
Key Offering: High-purity chemical intermediates, Custom synthesis services

Shanghai Canbi Pharma delivers pharmaceutical intermediates and services to research organizations and manufacturers globally. The company provides laboratory-scale to commercial-scale quantities and is advancing the logistics of chemical distribution across continents.

Production Capabilities:

• Offers certified pharmaceutical-grade intermediates

• Targets cGMP compliance across all manufacturing operations

---

5️⃣ 6. Hairui

Headquarters: Shanghai, China
Key Offering: Hairui Pharmaceutical Intermediates Line

Hairui is a global market leader in chemical intermediate production, supplying its proprietary synthesis methods to major pharmaceutical companies, research institutions, and contract development organizations worldwide. Its products are compatible with existing pharmaceutical manufacturing processes and quality systems.

Production Capabilities:

• Current high-purity chemical output: Over 50 tons/year

• Target: 80 tons/year production capacity by 2027

---

4️⃣ 7. SULI

Headquarters: Jiangsu, China
Key Offering: Pharmaceutical intermediates, High-purity chemicals

SULI serves over 200 pharmaceutical and biotechnology companies with critical chemical intermediates and is one of the largest suppliers in Eastern China. It plays a vital role in chemical supply chains across Asia and international markets.

Production Capabilities:

• Specialized in small-molecule pharmaceutical intermediates

• R&D into novel synthetic routes for improved efficiency and reduced cost.

---

3️⃣ 8. Cangzhou Enke Pharma-Tech

Headquarters: Hebei, China
Key Offering: (3-Chloropyrazin-2-yl)MethanaMine Hydrochloride with various purity specifications

Cangzhou Enke Pharma-Tech is China’s emerging pharmaceutical intermediate supplier, distributing products to research facilities and manufacturing plants nationwide and internationally. It has developed optimized synthesis protocols and successfully validated quality parameters with pharmaceutical clients.

Production Capabilities:

• Domestic pharmaceutical intermediate research and development

• Academic-industrial collaborations to scale production processes

---

2️⃣ 9. Sinocompound Catalysts

Headquarters: Shanghai, China
Key Offering: (3-Chloropyrazin-2-yl)MethanaMine Hydrochloride and other specialty chemicals

Sinocompound Catalysts is a key player in China’s chemical synthesis sector, specializing in catalytic processes and reaction optimization. Its research initiative is developing novel synthetic methodologies for complex pharmaceutical intermediates.

Production Capabilities:

• Aims to produce 30 tons/year of high-purity chemical intermediates

• Major chemical process optimization and scale-up projects underway

---

1️⃣ 10. Jiangsu Aikon Biopharmaceutical

Headquarters: Jiangsu, China
Key Offering: (3-Chloropyrazin-2-yl)MethanaMine Hydrochloride and related compounds

Jiangsu Aikon Biopharmaceutical specializes in the synthesis and purification of pharmaceutical intermediates, supporting over 1,000 research organizations, pharmaceutical companies, and CROs worldwide. It is a leader in chemical synthesis services and analytical method development.

Production Capabilities:

• End-to-end chemical synthesis solutions for pharmaceutical clients

• Strategic partnerships with pharmaceutical manufacturers and research institutions

Get Full Report Here: (3-Chloropyrazin-2-yl)MethanaMine Hydrochloride Market – View in Detailed Research Report

---

🌍 Outlook: The Future of (3-Chloropyrazin-2-yl)MethanaMine Hydrochloride Is More Efficient and Specialized

The (3-Chloropyrazin-2-yl)MethanaMine Hydrochloride market is undergoing significant transformation. While current applications are primarily focused on Acalabrutinib synthesis, the industry is investing heavily in process optimization, analytical method development, and scale-up capabilities for oncology drug manufacturing.

📈 Key Trends Shaping the Market:

• Rising global incidence of B-cell lymphomas and leukemias

• Regulatory approval expansions for Acalabrutinib in new indications and geographic markets

• Increasing adoption of targeted cancer therapies over traditional chemotherapy

• Pharmaceutical company-contract manufacturer alliances for stable intermediate supply

Get Full Report Here:
(3-Chloropyrazin-2-yl)MethanaMine Hydrochloride Market – View in Detailed Research Report

The companies listed above are not only supplying critical pharmaceutical intermediates—they’re supporting the advancement of precision oncology treatments worldwide.